drugset / Trial / NCT05014464
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study was to explore the efficacy of ALK-TKI in lung squamous cell carcinoma. Approximately 5% of lung adenocarcinomas have oncogenic fusions of EML-4 and ALK a mutation associated with tumorigenesis and migration.
Timeline
- Start
- 2021-11-13
- Primary completion
- 2026-06-01
- Completion
- 2027-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alectinib | Small molecule | 600 mg | Oral |
| Subject | Brigatinib | Small molecule | 180 mg | Oral |
| Subject | Crizotinib | Small molecule | 250 mg | Oral |
| Subject | Lorlatinib | Small molecule | 100 mg | Oral |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |